NCI Solicits Views on Cancer Study Invention Rights
Published Date: 6/27/2025
Notice
Summary
The National Cancer Institute’s Division of Cancer Prevention wants your thoughts on a new rule about who owns inventions made during certain cancer studies. This rule would affect groups working with NCI-funded projects that use special tech or drugs from NCI collaborators. If approved, it could change how intellectual property is shared in current and future studies, so get ready to weigh in soon!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
New NCI 'IP Option' for Collaborators
If you run or work for an entity that conducts Division of Cancer Prevention (DCP)‑funded clinical studies and your project uses a proprietary agent or technology provided by an NCI collaborator, a proposed standard policy called the “IP Option” could apply to you. The policy would be added as a term to applicable existing and future DCP funding agreements and could change how intellectual property developed by funding recipients is handled. The National Cancer Institute is asking for public comments on this proposed policy.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13802 — Government Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
The National Institutes of Health is offering special mouse strains that help study a rare heart rhythm disorder called CPVT. These mice let scientists explore how a key heart gene works and test new gene therapies. Researchers interested in this tool can access it now—no patents, just pure science ready to speed up discoveries!
2026-13612 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review and decide on important health research grant applications. These meetings keep sensitive info private to protect personal and commercial secrets. Researchers applying for grants and the public can expect no changes in funding timing or amounts, just careful, confidential reviews.
2026-13480 — Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
2026-13479 — Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
2026-13337 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on July 24, 2026, to review and evaluate important grant applications related to cancer, imaging, eye diseases, and reproductive health. These meetings protect private info and trade secrets, so they’re not open to the public. Researchers and organizations applying for grants should note the dates as these reviews impact funding decisions.
2026-13311 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review grant applications and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants or contracts should watch these dates closely, as funding decisions could impact their projects and budgets.
Previous / Next Documents
Previous: 2025-11857 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Survey of Construction: Questionnaire for Building Permit Official
The Department of Commerce wants to keep asking building permit officials some important questions about construction through a survey. They’re asking for your thoughts for 60 days before sending the survey for final approval. This helps make sure the survey isn’t too much work and keeps construction data accurate and up-to-date.
Next: 2025-11860 — Guidance on Referrals for Potential Criminal Enforcement
The Department of Commerce is rolling out new rules to spot and report serious rule-breaking that could lead to criminal charges. This affects businesses and people who follow federal rules, making sure only the really bad stuff gets punished. Starting May 9, 2025, expect sharper focus on criminal enforcement, helping save time and money by cutting down on unnecessary penalties.